I notice a lot of hub talk about the massive virtues of Bavi making it sound like the drug of the century. That reminds me of "Star Wars"----in the distant future in a galaxy far far away. While these optimistic claims may or may not be true, IMO it's not really where shareholders want to be focused "now".
What interests me is that we know "with fact certainty" that tax selling season is over in two more market days. I have seen a lot of market sells in size over the last few weeks that look like tax sales to me and I will be happy when that "at the market" pressure is over.
I like that at present I hear no Cotara discussion about any other subject than the shape of Phase III. IMO the only thing that makes sense for PPHM is to partner this drug and I feel there is a high probability that PPHM can get substantial enough amounts of upfront cash for a phase III drug to suspend ATM and materially improve balance sheet.
I am thankful that the delisting clock keeps getting reset to zero. I look forward to putting this issue behind us. (and I acknowlege that I am writing this on a down day with the stock once again below $1.00).
I very much like the recent work up Dr. Thorpe and his team have done in "imaging". IMO the key phrase in all the verbiage is that he considers this latest work as "proof of principle". Since I consider Dr. Thorpe to be one of the "adults in the room", IMO this technology is ready for a "clinical partner". There are large companies in this field such as GE and Abbott Labs to name two. It is clear to me from Dr. Thorpe's discussion that there are major markets for this product that would be attractive to such large companies. It will be very interesting to see what PPHM mgmt can bring to the table and how quickly in this area.
IMO there is a good probability that Bavi viral tests equal to or better than interferon for efficacy against Hepc and, of course, much better in AE's. I have done a lot of work in this area and rightly or wrongly have convinced myself there are big markets for this product not withstanding competition with new oral drugs (i.e. interferon replacement). Again, if results are good, it will be interesting to see how quickly PPHM mgmt can complete a deal in viral. IMO this particular test was done with specific target companies in mind and the upfront value might well exceed Cotara values.
Best Regards and Seasons Greetings,
RRdog
